Concord Biotech Ltd Performance
Open
1515
Traded Value (Cr)
5.80 Cr
Prev. Close
1501.3
VWAP
1517.27
Volume
30,416
Face Value
1
Concord Biotech Ltd Fundamentals
Concord Biotech Ltd Financials
Resistance and Support
₹1,562.27
PIVOT
 Resistance | |
|---|---|
| First Resistance | ₹1,594.533 |
| Second Resistance | ₹1,632.017 |
| Third Resistance | ₹1,664.283 |
 Support | |
|---|---|
| First Resistance | ₹1,524.783 |
| Second Resistance | ₹1,492.517 |
| Third Resistance | ₹1,455.033 |
| RSI | 35.529 |
| MACD | 28.586 |
| ADX | 53.846 |
| CCI | -106.238 |
Delivery and Volume
About Concord Biotech Ltd
Concord Biotech Ltd was originally incorporated as Servomed Pharmaceuticals Private Limited' at Ahmedabad, Gujarat as a Private Limited Company dated November 23, 1984, issued by the Registrar of Companies. Thereafter, name of the Company was changed to Concord Biotech Limited' dated February 16, 2001, which became a Public Company and a fresh Certificate of Incorporation dated November 7, 2001 was issued by the RoC. The Company is an India-based biopharma and one of the leading global developers and manufacturers of select fermentation-based APIs across immuno-suppressants and oncology in terms of market share, based on volume in supplying to over 70 countries including regulated markets, such as the United States, Europe and Japan, and India. Presently, it is engaged in research and development, manufacturing, marketing and selling of pharmaceutical products. Its API manufacturing facilities are located at Dholka and Limbasi, and formulations facility at Valthera in Gujarat. In 2000, the Company was acquired by the Promoter, Mr. Sudhir Vaid. In 2016, the Company launched formulation business in India as well as emerging markets, including Nepal, Mexico, Indonesia, Thailand, Ecuador, Kenya, Singapore and Paraguay, and have further expanded to the United States. It established a facility at Valthera, Gujarat. It set up a joint venture in Japan to grow business in 2018. In 2019, the Company received two ANDA approvals. It expanded their business into critical care segment in India. It commenced marketing of Mycophenolate Mofetil Capsules USP 250 mg. In 2020, Mycophenolate Sodium Tablets got launched in the US market. A second API manufacturing facility at Limbasi was launched, which commenced operations in July, 2021. As of March 31, 2022, the Company had 6 fermentation-based immunosuppressant APIs, including tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus and pimecrolimus. It had 3 manufacturing facilities in the state of Gujarat, India, comprising API manufacturing facilities in Dholka and Limbasi and a formulation manufacturing facility in Valthera, which were commercialized in 2000, 2021 and 2016, respectively. Their total annual installed fermentation capacity for APIs was 1,250 m3, as of March 31, 2022. It had a total of 41 manufacturing blocks and 387 reactors in the Dholka and Limbasi facilities. As of March 31, 2022, the annual installed production capacity of formulation facility in Valthera amounted to 522.64 million units, with an average dosage capability of 0.17 million tablets, 0.36 million capsules and 646.46 bottles of dry syrup per shift, which is defined as eight hours of production. The Company is planning to raise capital from Public by issuing o 20,925,652 Equity Shares through Offer for Sale.
Managing Director
SUDHIR JAIRAM VAID
Founded
1984
NSE Symbol
CONCORDBIO
Concord Biotech Ltd Management
| Name | Designation |
|---|---|
| SUDHIR JAIRAM VAID | Chairman & Managing Director |
| ANKUR VAID | Joint Managing Director & CEO |
| Ravi Kapoor | Non Executive Director |
| Rajiv Agarwal | Nominee |
| Utpal Sheth | Nominee |
| Amit Varma | Nominee |
| BHARTI KHANNA | Independent Director |
| ANIL KATYAL | Independent Director |
| Amitabh Thakore | Independent Director |
| Arvind Agarwal | Independent Director |
| Jayaram Easwaran | Independent Director |
| Mandayam Chakravarthy Sriraman | Independent Director |
| S Prakash | Vice President & CS |